New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
Abstract Background Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-α and γ agonist actions, respectively. It was granted marketing authorization in India in 2013 for...
Main Authors: | Upendra Kaul, Deven Parmar, K. Manjunath, Mitesh Shah, Krupi Parmar, Kishor P. Patil, Ashok Jaiswal |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-019-0884-3 |
Similar Items
-
Dual PPRαϒ Agonists for the Management of Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Antonio da Silva Menezes Junior, et al.
Published: (2023-08-01) -
PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
by: Francesca Colapietro, et al.
Published: (2023-01-01) -
Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
by: Shotaro Kamata, et al.
Published: (2023-08-01) -
Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience
by: Sujit Chaudhuri, et al.
Published: (2023-03-01) -
Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study
by: Liao X, et al.
Published: (2022-04-01)